Evidence guide · US

Probiotics with antibiotics: what a review of 21 meta-analyses says about preventing diarrhea

An umbrella review of 21 meta-analyses found probiotics linked to about half the risk of antibiotic-associated diarrhea, but with low certainty and no clear benefit over 65. What the evidence shows for children, C. difficile and safety.

Review type: research summary. This page summarises published research and product labels, cited below.

Diarrhea is a common side effect of antibiotics, and probiotics have been widely studied as a way to prevent it. A new umbrella review in Frontiers in Nutrition, published on October 27, 2026, pulled together 21 systematic reviews covering 170 unique randomized trials. Overall, probiotics were associated with about half the risk of antibiotic-associated diarrhea (risk ratio 0.54, 95% confidence interval 0.48 to 0.61). The authors report no increase in adverse events, but four reviews recorded that outcome and only two could be combined.

Short answer: the overall signal is consistent, but the certainty is low. In the four reviews that reported on adults over 65, no clear benefit was seen, and the authors say that age pattern still needs confirmation. The authors stress that the findings do not show that any specific probiotic product is effective, and should not be used to support class-wide or product-specific claims. The stronger strain-specific evidence is in children. For C. difficile, the 2017 Cochrane review found a lower risk in trials with a high starting risk, not a benefit tied to one strain.

What the umbrella review did

The authors are at Baiyin City Central Hospital, with the corresponding author at Lanzhou University. They searched eight databases up to March 21, 2026 for systematic reviews with meta-analyses of randomized trials of oral probiotics to prevent antibiotic-associated diarrhea. They found 21. Together those reviews included 478 trial entries, but many trials appeared in several reviews, so there were 170 unique trials. The authors rated each review's quality with a standard tool (AMSTAR 2), measured how much the reviews overlapped, and then pooled the reviews' own results in a "second-order" meta-analysis. The protocol was registered in advance on PROSPERO.

What it found

  • Overall: probiotics were associated with a lower risk of antibiotic-associated diarrhea (risk ratio 0.54, 95% confidence interval 0.48 to 0.61). Because the reviews share many trials, the authors say this estimate is probably more precise than the evidence warrants.
  • Checks: leaving out one review at a time gave risk ratios of 0.54 to 0.55. Restricting to reviews with little overlap gave weaker, less precise estimates (0.59 to 0.63).
  • Children and adults: estimates were similar in children (risk ratio 0.46) and adults (0.55).
  • Older adults: in the four reviews that reported on people over 65, no clear benefit was seen (risk ratio 0.96, 95% confidence interval 0.85 to 1.08).
  • Dose: an exploratory comparison based on three overlapping reviews found a lower estimate for at least 5 billion colony-forming units (CFU) a day than for lower doses. The authors say this comparison is confounded by age and product and cannot be applied to individual products.
  • Safety: four of the 21 reviews reported adverse events. Only two, both using a risk difference, could be pooled, and that result showed no difference (risk difference 0.00, 95% confidence interval -0.01 to 0.01).

Why the certainty is low

Only one of the 21 reviews was rated high quality, and 13 were rated critically low. Of the 210 possible pairs of reviews, 71 overlapped very heavily. The trials themselves used many different organisms, mostly Lactobacillus, Bifidobacterium and Saccharomyces, alone or in mixtures, at different doses and in different formulations, and 18 of the 21 reviews evaluated multi-strain or mixed products. The authors call the result low-certainty evidence and call for high-quality, strain-specific trials. The NHS makes a related point: different probiotics may have different effects, and a type that helps with one problem may not help with another.

Children: the clearest evidence

A 2019 Cochrane review of 33 trials in 6,352 children found antibiotic-associated diarrhea in 8% of children given probiotics and 19% of controls (risk ratio 0.45; moderate-certainty evidence), so about nine children would need a probiotic to prevent one case. The benefit was credible mainly for high doses of at least 5 billion CFU a day, where about six children would need treatment to prevent one case. The authors name Lactobacillus rhamnosus and Saccharomyces boulardii as examples of high-dose probiotics whose benefit should be confirmed in a large trial, and say it is premature to draw firm conclusions about other probiotics. A 2022 position paper from ESPGHAN, the European pediatric gastroenterology society, makes a recommendation only when at least two trials of a similar, well-defined strain are available, and says probiotics with no documented health benefits should be discouraged.

Older adults: a large UK trial was negative

The no-benefit finding in older adults matches PLACIDE, a trial in five NHS hospitals. It enrolled 2,981 inpatients aged 65 or over who were taking antibiotics and gave them either capsules with two lactobacillus and two bifidobacterium strains (60 billion organisms a day) or a placebo for 21 days. Antibiotic-associated diarrhea occurred in 10.8% of the probiotic group and 10.4% of the placebo group (risk ratio 1.04). C. difficile diarrhea was uncommon: 0.8% versus 1.2%, a difference that was not statistically significant. The trial concluded that this probiotic seems unlikely to benefit older patients exposed to antibiotics. NCCIH also notes that a benefit has not been demonstrated in elderly people, though it is unclear whether that reflects no effect or too few studies.

C. difficile

C. difficile is a bacterium that can cause diarrhea after antibiotics, from mild to severe. NCCIH says it is more common in people who take antibiotics long-term and in elderly people, and that it can spread in hospitals and nursing homes. A 2017 Cochrane review of 31 trials with 8,672 patients found C. difficile-associated diarrhea in 1.5% of people given probiotics and 4.0% of controls (risk ratio 0.40; moderate certainty). In a post hoc analysis, a benefit was seen where the baseline risk was above 5% (3.1% versus 11.6%; risk ratio 0.30), and not where it was 5% or lower. The authors concluded that short-term probiotic use alongside antibiotics appears safe and effective in patients who are not immunocompromised or severely debilitated, and that hospital patients, particularly those at high risk, should be told about the potential benefits and harms.

Safety

The NHS says that for most people probiotics appear to be safe, and that people with a healthy immune system should not get unpleasant side effects. NCCIH says the risk of harm is greater in people with severe illness or a weakened immune system, and that severe or fatal infections have been reported in premature infants given probiotics, a risk the US Food and Drug Administration has warned health care providers about. The Cochrane review in children found no serious adverse events attributed to probiotics in its trials. It notes separate observational reports, not included in the review, of serious adverse events in severely debilitated or immunocompromised children, including those with central venous catheters. Product quality is another issue: the NHS says probiotics are generally classed as food rather than medicine, and that, because of the way they are regulated, it cannot always be sure a product contains the bacteria stated on the label, enough bacteria to have an effect, or bacteria that survive long enough to reach the gut, and NCCIH notes that some products have contained organisms not listed on the label.

Our view

  • The overall signal for probiotics during antibiotics is consistent across many reviews, but 20 of the 21 reviews were rated low or critically low quality, and many of the same trials appear in more than one review. The authors also report a possible small-study effect. Treat "probiotics halve antibiotic diarrhea" as a low-certainty average, not a promise.
  • In children, the 2019 Cochrane review found moderate-certainty evidence, and the high-dose subgroup (at least 5 billion CFU a day) was the one it called credible. For C. difficile, the 2017 Cochrane review found a lower risk only in a post hoc split of trials with a starting risk above 5%, and it says hospital patients, particularly those at high risk, should be told the potential benefits and harms.
  • For adults over 65, four reviews in the umbrella analysis did not show a clear benefit, and the authors say that comparison needs confirmation. PLACIDE, a large trial in NHS hospitals, found no benefit from the preparation it studied.
  • Results belong to strains, not to the word "probiotic" on a label. ESPGHAN makes a recommendation only when at least two trials of a similar, well-defined strain are available, and says probiotics with no documented health benefits should be discouraged.
  • If you have an existing health condition or a weakened immune system, the NHS says to talk to a doctor before taking a probiotic supplement. NCCIH says the risk is greater in severe illness or with a compromised immune system. For a premature baby, NCCIH says severe or fatal infections have been reported and the US Food and Drug Administration has warned health care providers. Serious adverse events have also been reported, outside the Cochrane trials, in severely debilitated or immunocompromised children, including those with a central venous catheter.

US rules

In the United States, NCCIH says the FDA may regulate a probiotic as a dietary supplement, a food ingredient or a drug, depending on its intended use, and that many are sold as dietary supplements, which do not need FDA approval before they are marketed. FDA does not approve dietary supplements for safety and effectiveness before they are sold. FDA advises talking with a doctor or pharmacist before using a supplement, and a serious reaction can be reported through FDA's Safety Reporting Portal.

FAQ

Should I take a probiotic with my antibiotics?

For children, the 2019 Cochrane review found moderate-certainty evidence of fewer cases of antibiotic-associated diarrhea. For adults under 65, the umbrella review's average also showed a lower risk, at low certainty, and the authors say this does not show that any specific product is effective. For adults over 65, that review and the PLACIDE trial did not show a clear benefit. NCCIH says: "Don't use probiotics as a reason to postpone seeing your health care provider about any health problem."

Does yogurt count?

Not necessarily. The NHS says there is likely to be a huge difference between the pharmaceutical-grade probiotics that show promise in trials and the yogurts and supplements sold in shops.

Does a higher CFU count work better?

In children, the Cochrane review found a credible benefit for at least 5 billion CFU a day. In the umbrella review, the dose comparison was exploratory and confounded by age and product, so a bigger number on a label is not proof that a product works.

Can probiotics prevent C. difficile?

The 2017 Cochrane review found moderate-certainty evidence of a lower risk of C. difficile-associated diarrhea. In a post hoc analysis, that lower risk appeared in trials with a starting risk above 5% and not in trials at 5% or below. Inpatient and outpatient results in the review were similar, so a hospital stay by itself is not what the subgroup measured. NCCIH notes that most of the included studies involved hospital patients.

Sources

These are the documents this page relies on.

  1. Probiotics for the prevention of antibiotic-associated diarrhea: an umbrella review and second-order meta-analysis of 21 systematic reviews covering 170 unique randomized controlled trials. Front Nutr. 2026;13:1994645Frontiers in Nutrition (PubMed 43010964)
  2. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4:CD004827Cochrane Database of Systematic Reviews (PubMed 31039287)
  3. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12:CD006095Cochrane Database of Systematic Reviews (PubMed 29257353)
  4. A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhea in older people admitted to hospital (PLACIDE). Health Technol Assess. 2013;17(57):1-140NIHR Health Technology Assessment (PubMed 24309198)
  5. Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr. 2023;76(2):232-247Journal of Pediatric Gastroenterology and Nutrition (PubMed 36219218)
  6. Probiotics: usefulness and safetyNIH National Center for Complementary and Integrative Health
  7. ProbioticsNHS
  8. Information for consumers on using dietary supplementsUS Food and Drug Administration
  9. How to report a problem with dietary supplementsUS Food and Drug Administration